| Dr Bonda Ann Abide, MD, MPH | |
|
1120 Avon Pl, Greenville, MS 38701-8305 | |
| (662) 931-0490 | |
| Not Available |
| Full Name | Dr Bonda Ann Abide |
|---|---|
| Gender | Female |
| Speciality | Preventive Medicine - Public Health & General Preventive Medicine |
| Location | 1120 Avon Pl, Greenville, Mississippi |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1841597861 | NPI | - | NPPES |
| Mailing Address | Practice Location Address |
|---|---|
| Dr Bonda Ann Abide, MD, MPH 1120 Avon Pl, Greenville, MS 38701-8305 Ph: (662) 931-0490 | Dr Bonda Ann Abide, MD, MPH 1120 Avon Pl, Greenville, MS 38701-8305 Ph: (662) 931-0490 |
News Archive
EntreMed, Inc., today announced the publication of preclinical data for its Phase 2 oncology drug candidate, ENMD-2076 an Aurora A/angiogenic kinase inhibitor, which demonstrated significant activity against multiple myeloma cell lines and in MM models in vivo. Results of the study, conducted by EntreMed's collaborator, Sherif Farag, M.D., Ph.D., and colleagues at the Indiana University School of Medicine, were published in the on-line version of the British Journal of Haematology on June 15, 2010 and are scheduled to be published in print in the August 1, 2010 issue.
In a recent study, U.S. researchers have reprogrammed cells found in circulating blood into cells that are molecularly and functionally indistinguishable from embryonic stem cells, a revolutionary achievement that provides a readily accessible source of stem cells and an alternative to harvesting embryonic stem cells.
When the Food and Drug Administration issued an emergency-use authorization for the investigational pharmaceutical remdesivir to treat COVID-19 on May 1, in part it was due to pioneering work performed by pharmaceutical chemists at the University of Kansas School of Pharmacy in 1990.
Patients with advanced stage prostate cancer who receive radiation therapy immediately after surgery to remove their prostate live longer without their cancer returning than patients who do not receive radiation after surgery, according to a study presented October 17, 2005, at the American Society for Therapeutic Radiology and Oncology's 47th Annual Meeting in Denver.
› Verified 1 days ago